BLUDE Immucor (MM)

COLCHESTER, Conn., Oct. 19 /PRNewswire/ -- Scott+Scott, LLC (http://www.scott-scott.com/ ) represents investors in a securities class action filed today in the United States District Court for the Northern District of Georgia against Immucor, Inc. ("Immucor" or the "Company") (NASDAQ:BLUDE) and certain of its former and current officers. Immucor securities purchasers between January 7, 2005, and August 29, 2005, inclusive (the "Class Period") are putative class members. If you purchased Immucor securities during the Class Period and wish to serve as lead plaintiff, you must so move the Court no later than October 31, 2005. If you wish to discuss this action or have questions concerning your rights as a class member, please contact Scott+Scott partner Neil Rothstein at (800/332-2259, ext. 22, cell 619/251-0887, or via e-mail at ). Scott+Scott will provide class members with case materials and answer all questions regarding participation and rights. There is no cost or fee to class members. The complaint alleges that during the Class Period, Immucor and certain of its former and current officers violated provisions of the Securities Exchange Act of 1934 (the "Exchange Act") by issuing a series of material misrepresentations. Specifically, the complaint alleges that, among other things, defendants misrepresented that Immucor's financial statements and disclosures fairly and accurately reflected the Company's results of operations as required by the Generally Accepted Accounting Principles ("GAAP") and the Exchange Act. Further, it is alleged that defendants' Sarbanes-Oxley certifications during the Class Period were also false and misleading, as the Company knowingly or with severe recklessness lacked adequate internal controls and failed to keep proper books and records in violation of their well publicized Code of Corporate Conduct. On August 26, 2005, the truth began to surface when Immucor issued a press release announcing that the Securities and Exchange Commission ("SEC") had issued a formal order as part of its investigation related to payments made by the Company's Italian subsidiary to individuals associated with government medical facilities. Three days later, Immucor announced that defendant Chief Executive Officer Steven C. Ramsey resigned. Further, while the stock price was artificially traded, insiders sold approximately $5 million of stock. In response to this news, shares of Immucor dropped from a closing price of $28.61 on August 25, 2005, to close at $24.00 per share on August 30, 2005. Yesterday, October 18, 2005, almost two months after the market learned of the SEC's formal order, shares again closed at $24.00. Please contact Scott+Scott, LLC for more information. DATASOURCE: Scott+Scott, LLC CONTACT: Neil Rothstein 1-800-332-2259, ext. 22, cell +1-619-251-0887, or Web site: http://www.scott-scott.com/

Copyright